Eric J. Sieczka

Eric J. Sieczka is the Chairman, President and CEO of Epsilon Imaging. Mr. Sieczka has spent over 20 years commercializing technologies and building Michigan-based enterprises. His experience ranges from technology creation, product development and operations management to financing and strategic transactions. He is also the co-founder, and sits on the Board, of Pixel Velocity Incorporated, another investor-backed early stage technology business and the former parent company of Epsilon Imaging. Prior to starting Pixel Velocity and Epsilon Imaging, Mr. Sieczka was the co-founder and Vice President of Operations for EOTech Inc, where he built the operations from a start-up product concept, into a world-class, fully integrated manufacturing facility with optical, electrical, and mechanical design capabilities servicing markets around the globe. Prior to his departure, Mr. Sieczka helped orchestrate the successful sale of EOTech to L-3 Communications (a $10B publicly traded defense contractor). Mr. Sieczka has eight patents covering an array of electro-optic technologies. He holds a BSEE degree from Kettering Institute and an MBA from the Ross School of Business at the University of Michigan.

Philip M. Croxford is an experienced medical device CEO who has had a track record of delivering exceptional commercial and financial performance across a wide range of modalities and international markets. Most recently, he was President and CEO of an early stage breast cancer diagnostic company, Gamma Medica, Inc. Prior, he was Global President and CEO at LifeCell, a bio-tissue technology company, sold by APAX Partners, a private equity firm, to Allergan. He has also held similar level positions with Getinge AB, Draeger Medical, Arrow International Inc. (now Teleflex), Johnson & Johnson and Smith & Nephew.  Mr. Croxford has had extensive early stage, PE owned and “midcap” sized organization experience, with a track record of developing commercialization plans that delivered a substantial change in top and bottom line growth.  He is also a board member of Vital Therapies Inc. [VTL – NASDAQ], a biotech company that has developed an extra-corporeal liver assist therapy to treat terminal and chronic liver disease.  He was awarded a BSc(Hons) in Pharmacy from the University Manchester, England and a MBA from Edinburgh Business School, Heriot Watt University, UK.  He is also member of the Pharmaceutical Society of Great Britain and a Chartered Member of the Institute of Marketing, UK.

Thomas C. Kinnear

Thomas C. Kinnear is J. Maynard Phelps Professor of Business and Marketing at the Ross School of Business at the University of Michigan. He was the founding Executive Director of Samuel Zell and Robert H. Lurie Institute for Entrepreneurial Studies, a position he held for 14 years. He has received awards from the University of Michigan for teaching excellence and service to the University. He previously held a faculty appointment at the University of Western Ontario, and visiting appointments at Harvard University, Stanford University, and the European Management Institute (INSEAD) at Fontainebleau, France. His teaching and research interests are in the areas of entrepreneurial studies, strategic marketing planning, marketing and public policy, and market-based management. He is co-author of several books including Modern Marketing Research, (Thomson) and Principles of Marketing (Harper Collins). He is CEO and Chair of the Board of Directors of the Venture Michigan Corporation, a $200 million venture capital fund of funds, and is a Director and the former Chair of the American Marketing Association. He is active in the entrepreneurial community as a co-founder, advisor, angel investor, and Board member of several startup companies. He is also a member of the investment committee for EDF Ventures and Chairs this committee for Arboretum Ventures. Dr. Kinnear holds an undergraduate degree and LLD (honoris causa) from Queen’s University at Kingston, Ontario, an MBA from Harvard University, and a Ph.D. in Business Administration from the University of Michigan.

Matthew O'Donnell

Matthew O’Donnell, Ph.D. is the Frank and Julie Jungers Dean of Engineering and also a Professor of Bioengineering at the University of Washington. He has won numerous awards, including the Achievement Award from the IEEE Ultrasonics, Ferroelectrics & Frequency Control Society. He is a fellow of the IEEE and AIMBE and is a member of the National Academy of Engineering. His most recent research has explored new imaging modalities in biomedicine, including elasticity imaging, in vivo microscopy, optoacoustic arrays, optoacoustic contrast agents for molecular imaging and therapy, thermal strain imaging, and catheter based devices. He has previously held faculty appointments at Washington University and the University of Michigan, and a visiting appointment at Yale University. He worked several years with General Electric Corporate Research in Schenectady, NY, on medical electronics, including MRI and ultrasound imaging systems. Dr. O’Donnell has over 300 archival publications and 55 patents. Dr. O’Donnell has a BS and Ph.D. in Physics, University of Notre Dame.

James Hamilton

James Hamilton, Ph.D., Advanced imaging expert and Epsilon Imaging Co-founder. Dr. Hamilton has been developing state of the art imaging systems for the medical, defense and scientific communities for the over 20 years. He worked at GE Medical Systems ultrasound group, working on next generation blood flow imaging and image quality enhancements. Later he joined General Dynamics where he developed wavefront sensing techniques for electro-optic systems and image restoration algorithms. Dr. Hamilton served as Chief Technology Officer and Vice President of Engineering at Epsilon Imaging since its inception in 2008 to 2015, leading and managing the successful technology design and development launch of the EchoInsight platform. Dr. Hamilton holds a B.S. from the University of Rochester, and M.S. and Ph.D. degrees in physics from the University of Michigan. He has authored numerous journal publications and holds four patents.